



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.


Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections

Hanan Polansky , Gillad Lori

PII: S0924-8579(20)30128-X
DOI: <https://doi.org/10.1016/j.ijantimicag.2020.105971>
Reference: ANTAGE 105971



To appear in: *International Journal of Antimicrobial Agents*

Please cite this article as: Hanan Polansky , Gillad Lori , Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections, *International Journal of Antimicrobial Agents* (2020), doi: <https://doi.org/10.1016/j.ijantimicag.2020.105971>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier B.V.

Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections

Hanan Polansky¹, (corresponding author), Gillad Lori¹

¹The Center for the Biology of Chronic Disease (CBCD)

616 Corporate Way, Suite 2-3665, Valley Cottage, NY 10989

607-256-6070

hpolansky@cbcd.net

gillad@cbcd.net

Running title: *COVID-19, Gene-Eden-VIR, Novirin*

Sir,

The novel coronavirus (COVID-19) outbreak imposes a significant threat to global health with an estimated R_0 of 2.24-4.08 and fatality rate of 3.4%. Samples collected from COVID-19 patients revealed that the novel virus is a betacoronavirus, closely related to the human Severe Acute Respiratory Syndrome (SARS-CoV) with 79.5% sequence identity¹. In addition, SARS-CoV and COVID-19 have an almost identical 3-Chymotrypsine-Like protease (3CLpro) amino acid sequences, with 96% identity and 99% similarity². To expedite the development of new treatments, several existing drugs, which were found effective against RNA viruses and particularly against SARS, are currently tested for their effect on the COVID-19 virus.

Gene-Eden-VIR/Novirin is a patented herbal broad-spectrum antiviral treatment. Its formula includes five ingredients: a 100 mg extract of quercetin, a 150 mg extract of green tea, a 50 mg extract of cinnamon, a 25 mg extract of licorice, and 100 μ g of selenium. Clinical trials showed that Gene-Eden-VIR/Novirin is effective against several viruses, including the Human Papillomavirus (HPV)³, Herpes Simplex Virus⁴ (HSV), Epstein-Barr virus (EBV), and human Cytomegalovirus (hCMV). In the next section, we review evidence on the effect of the Gene-Eden-VIR/Novirin five ingredients on betacoronaviruses, and specifically, the SARS-CoV virus.

Quercetin and the active ingredients in green tea, called catechins, are polyphenols known as flavonoids. They have a variety of anti-inflammatory, anti-oxidant and anti-enzymatic activities. Quercetin and its derivatives as well as different catechins found in green tea were found to inhibit the SARS proteases⁵. Specifically, Thi Nguyen et al. Found that both Epigallocatechin Gallate and Quercetin inhibit the SARS main protease, 3CLpro with an IC_{50}

of 73uM *in vitro*. In addition, Ji Young Park et al. reported that Quercetin inhibits both the SARS Proteases, 3CLpro and PLpro, and the Middle Eastern Respiratory Syndrome virus (MERS) 3CLpro protease with an IC₅₀ of 52.7uM, 8.6uM and 34.8uM respectively, *in vitro*⁶. Quercetin also modulates the cellular unfolded protein response (UPR). As coronaviruses can utilize the UPR to complete different stages of the viral life cycle during infection, Nabirotkin et al. suggested that quercetin may have anti-coronavirus effects through its modulation of this pathway⁷.

Cinnamon extract has anti RNA viral effects⁸. Min Zuang et al. showed that the extract inhibited wild type SARS infection *in vitro* with an IC₅₀ of 43uM. The proposed possible mechanism was blocking cell entry via endocytosis.

Licorice extract, derived from the root of *Glycyrrhiza Glabra*, has both broad antiviral and immunostimulating effects⁹. The plant was also reported to have specific anti-SARS effects. Brush et al. demonstrated that the herb stimulates the proliferation and activation of lymphocytes in human subjects. This can be of major importance in the coronavirus infections, since immunocompromised patients may be particularly at risk.

Selenium (Se) is an important trace element in redox regulation. Its antioxidative function is exerted via its incorporation, in the form of selenocysteine, into a group of proteins called selenoproteins¹⁰. Se deficiency leads to increased levels of reactive oxygen species (ROS) and oxidative stress, and results in a decreased response of the immune system to viruses, and an increased rate of mutation of RNA viruses. The combination of an increase in viral rate of mutation with a decrease in the immune response, has been linked to increased virulence, as it may give rise to a larger population of quasispecies, of which new, more pathogenic

quasispecies may emerge. M. Harthill¹¹ suggested that this mechanism, which has been observed for other RNA viruses in Se deficient mice models, also occurred in the SARS-CoV outbreak, which emerged in areas of low Se soil in China, such as Wuhan city. Studies showed that Se supplementation to Se deficient patients increased the immune response to viral infections, and decreased the virulence of several viruses, in some cases to the point of complete prevention of the disease¹⁰.

In summary, in this paper we described the effects of Gene-Eden-VIR/Novirin ingredients on betacoronaviruses, and specifically SARS-CoV. We chose SARS-CoV because of its high level of sequence identity to COVID-19. We showed that Gene-Eden-VIR/Novirin ingredients exert a variety of antiviral effects on betacoronaviruses, and SARS-CoV, including inhibition of cell entry and infection, inhibition of replication, inhibition of the viral proteases, enhancing the antiviral immune response, and reducing virulent quasispecies formation. We regard the evidence presented in this paper as first indication of efficacy. Next, we are planning to collect clinical data on the effect of Gene-Eden-VIR/Novirin on the SARS-CoV-2 virus from users of the treatments. We will use this clinical data to further our understanding of the effects of the treatments on individuals at risk and those infected with the virus.

Declarations

Funding: No funding

Competing Interests: Hanan Polansky is the inventor of the Gene-Eden-VIR/Novirin formula. Gillad Lori has no conflict of interest.

Ethical Approval: Not required

References

- ¹ R. Lu, X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet*. 2020; Volume 395, Issue 10222: 391-393
- ² M. Stoermer. Homology Models of Coronavirus 2019-nCoV 3CLpro Protease. *ChemRxiv*. 2020. <https://doi.org/10.26434/chemrxiv.11637294.v3>
- ³ H. Polansky, E. Itzkovitz, A. Javaherian. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus. *Drug Design, Development and Theory*. 2017;11: 575–583
- ⁴ H. Polansky, A. Javaherian, E. Itzkovitz. Clinical Trial of Herbal Treatment Gene-Eden-VIR/Novirin in Oral Herpes. *J Evid Based Integr Med*. 2018; 23: 2515690X18806269
- ⁵ T.Y.H. Nguyen, H.J. Woo, H.K. Kang, V.D. Nguyen, Y.M. Kim, D.W. Kim, S.A Ahn, Y. Xia, D. Kim. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in *Pichia pastoris*. *Biotechnology Letters*. 2012; 34:831–838
- ⁶ J.Y. Park, H.J. Yuk, H.W. Ryu, S.H. Lim, K.S. Kim, K.H. Park, Y.B. Ryu & W.S. Lee. Evaluation of polyphenols from *Broussonetia papyrifera* as coronavirus protease inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*. 2017;32(1): 504-512
- ⁷ S. Nabirotkin, A. Peluffo¹ , J. Bouaziz¹ and D. Cohen. Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19. Preprints. March 2020
- ⁸ M. Zhuanga, H. Jiangc, Y. Suzukia, X. Lia, P. Xiaoa, T. Tanakad, H. Ling ,B. Yange, H. Saitoha, L. Zhangc, C. Qinc, K. Sugamuraf, T. Hattori. Procyanidins and butanol extract of *Cinnamomi Cortex* inhibit SARS-CoV infection. 2009; 82(1):73-81

-
- ⁹ J. Brush , E. Mendenhall, A. Guggenheim, T. Chan, E. Connelly, A. Soumyanath, R. Buresh, R. Barrett, H. Zwickey. The Effect of Echinacea purpurea, Astragalus membranaceus and Glycyrrhiza glabra on CD69 Expression and Immune Cell Activation in Humans. *Phytother. Res.*2006: 20(8): 687–695
- ¹⁰ O. Guillin, C. Vindry, T. Ohlmann, L. Chavatte. Selenium, Selenoproteins and Viral Infection. *Nutrients.* 2019;11:2101
- ¹¹ M. Harthill. Review: Micronutrient Selenium Deficiency Influences Evolution of Some Viral Infectious Diseases. *Biological Trace Element Research.* 2011; 143: 1325–1336